Upon IND clearance, KemPharm anticipates initiating KP1077 Phase 2 IH trial as early as the second half of 2022
CELEBRATION, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS:KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder.
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/Chipotle%20Mexican%20Grill%20lunch%20by-%20dennizn%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
